These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34268879)

  • 1. An evidence-based, risk-adapted algorithm for antifungal prophylaxis reduces risk for invasive mold infections in children with hematologic malignancies.
    Dutta A; Ikwuezunma A; Castellanos MI; Brackett J; Reddy K; Mahajan P; Marshburn AM; Kamdar K; Paek H; Palazzi DL; Rabin KR; Scheurer ME; Gramatges MM
    Pediatr Blood Cancer; 2021 Dec; 68(12):e29228. PubMed ID: 34268879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential systematic anti-mold prophylaxis with micafungin and voriconazole results in very low incidence of invasive mold infections in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Rosillo C; Avila AM; Huang YT; Devlin S; Cho C; Montoro J; Maloy MA; Papanicolaou GA; Barba P; Perales MA
    Transpl Infect Dis; 2018 Aug; 20(4):e12897. PubMed ID: 29668073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. European Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) host factors and invasive fungal infections in patients with haematological malignancies.
    Hoenigl M; Strenger V; Buzina W; Valentin T; Koidl C; Wölfler A; Seeber K; Valentin A; Strohmeier AT; Zollner-Schwetz I; Raggam RB; Urban C; Lass-Flörl C; Linkesch W; Krause R
    J Antimicrob Chemother; 2012 Aug; 67(8):2029-33. PubMed ID: 22566591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies.
    Cornely OA; Ullmann AJ; Karthaus M
    Blood; 2003 May; 101(9):3365-72. PubMed ID: 12393455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Antifungal Prophylaxis Continuation or Discontinuation After Allogeneic Hematopoietic Cell Transplant on the Incidence of Invasive Mold Infection.
    Ross JA; Lee B; Ma H; Tegtmeier B; Nanayakkara D; Dickter J; Spielberger R; Smith E; Pullarkat V; Forman SJ; Taplitz R; Nakamura R; Al Malki M; Dadwal SS
    Open Forum Infect Dis; 2024 Aug; 11(8):ofae409. PubMed ID: 39135965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients.
    Glasmacher A; Prentice A; Gorschlüter M; Engelhart S; Hahn C; Djulbegovic B; Schmidt-Wolf IG
    J Clin Oncol; 2003 Dec; 21(24):4615-26. PubMed ID: 14673051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and Risk Factors for Breakthrough Invasive Mold Infections in Acute Myeloid Leukemia Patients Receiving Remission Induction Chemotherapy.
    Patel HP; Perissinotti AJ; Patel TS; Bixby DL; Marshall VD; Marini BL
    Open Forum Infect Dis; 2019 May; 6(5):ofz176. PubMed ID: 31123689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective study on the incidence and outcome of proven and probable invasive fungal infections in high-risk pediatric onco-hematological patients.
    Cesaro S; Tridello G; Castagnola E; Calore E; Carraro F; Mariotti I; Colombini A; Perruccio K; Decembrino N; Russo G; Maximova N; Baretta V; Caselli D
    Eur J Haematol; 2017 Sep; 99(3):240-248. PubMed ID: 28556426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antifungal prophylaxis in neutropenic patients with hematologic malignancies: is there a real benefit?
    Böhme A; Karthaus M; Hoelzer D
    Chemotherapy; 1999; 45(3):224-32. PubMed ID: 10224346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation.
    Roman E; Osunkwo I; Militano O; Cooney E; van de Ven C; Cairo MS
    Pediatr Blood Cancer; 2008 Feb; 50(2):325-30. PubMed ID: 17514732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies.
    Maertens J
    Eur J Haematol; 2007 Apr; 78(4):275-82. PubMed ID: 17241370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mixed treatment comparison of prophylaxis against invasive fungal infections in neutropenic patients receiving therapy for haematological malignancies: a systematic review.
    Pechlivanoglou P; Le HH; Daenen S; Snowden JA; Postma MJ
    J Antimicrob Chemother; 2014 Jan; 69(1):1-11. PubMed ID: 23975736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience.
    Busca A; Cinatti N; Gill J; Passera R; Dellacasa CM; Giaccone L; Dogliotti I; Manetta S; Corcione S; De Rosa FG
    Front Cell Infect Microbiol; 2021; 11():805514. PubMed ID: 35071052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimizing the risk of recurrent or progressive invasive mold infections during stem cell transplantation or further intensive chemotherapy.
    Grigg A; Slavin M
    Transpl Infect Dis; 2008 Feb; 10(1):3-12. PubMed ID: 17605732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current Status and Future Perspectives of Primary Antifungal Prophylaxis in Patients with Hematological Malignancies-Review].
    Li Y; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):627-632. PubMed ID: 28446325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary prophylaxis of invasive fungal infections with combination antifungal therapy and G-CSF-mobilized granulocyte transfusions in three children with hematological malignancies.
    Grigull L; Beilken A; Schmid H; Kirschner P; Sykora KW; Linderkamp C; Donnerstag F; Goudeva L; Heuft HG; Welte K
    Support Care Cancer; 2006 Jul; 14(7):783-6. PubMed ID: 16482446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of primary antifungal prophylaxis in patients with haematological malignancies.
    Pagano L; Caira M
    Clin Microbiol Infect; 2014 Jun; 20 Suppl 6():19-26. PubMed ID: 24372659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project.
    Pagano L; Caira M; Nosari A; Cattaneo C; Fanci R; Bonini A; Vianelli N; Garzia MG; Mancinelli M; Tosti ME; Tumbarello M; Viale P; Aversa F; Rossi G;
    Haematologica; 2011 Sep; 96(9):1366-70. PubMed ID: 21565903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A risk prediction score for invasive mold disease in patients with hematological malignancies.
    Stanzani M; Lewis RE; Fiacchini M; Ricci P; Tumietto F; Viale P; Ambretti S; Baccarani M; Cavo M; Vianelli N
    PLoS One; 2013; 8(9):e75531. PubMed ID: 24086555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of a standardized screening protocol for diagnosis of invasive mold infections in children with hematologic malignancies.
    Cohn SM; Pokala HR; Siegel JD; McClay JE; Leonard D; Kwon J; Timmons CF; Winick NJ
    Support Care Cancer; 2016 Dec; 24(12):5025-5033. PubMed ID: 27518197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.